Antibody-Drug Conjugate Shows Efficacy in Heavily Treated Cancers

Antibody-Drug Conjugate Shows Efficacy in Heavily Treated Cancers
An investigational antibody-drug conjugate made of the HER2-targeting antibody trastuzumab (marketed as Herceptin and others) attached to a kind of chemotherapy compound has demonstrated notable efficacy in heavily treated patients with breast and other cancer types, a Phase 1 trial showed. "Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study" was published in The Lancet Oncology. Around a quarter of breast cancer tumors have high levels of HER2, a protein that can drive tumor growth. These tumors often develop resistance to standard treatments, so there is a need for new strategies to treat them. The antibody therapy Herceptin (trastuzumab) can bind to HER2, blocking its activity. This can be beneficial for patients, and when resistance appears, patients benefit from an antibody-drug conjugate called Kadcyla (trastuzumab emtansine). This treatment combines the antibody in Herceptin, trastuzumab, with the cytotoxic agent DM1. But what happens when patients develop resistance to both Herceptin and Kadcyla? In the new study, researchers examined a different antibody-drug conjugate, which
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.